[go: up one dir, main page]

AR077016A1 - Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales - Google Patents

Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales

Info

Publication number
AR077016A1
AR077016A1 ARP100102006A ARP100102006A AR077016A1 AR 077016 A1 AR077016 A1 AR 077016A1 AR P100102006 A ARP100102006 A AR P100102006A AR P100102006 A ARP100102006 A AR P100102006A AR 077016 A1 AR077016 A1 AR 077016A1
Authority
AR
Argentina
Prior art keywords
tau
antibody
treatment
brain diseases
phosphorylated
Prior art date
Application number
ARP100102006A
Other languages
English (en)
Inventor
Fiona Grueninger
Bernd Bohrmann
Ulrich Goepfert
Hans-Willi Krell
Laurence Ozmen
Olaf Mundigl
Michael Schraeml
Sonja Offner
Valeria Lifke
Walter Huber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR077016A1 publication Critical patent/AR077016A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un anticuerpo, que se une a la tau fosforilada en la serina 422 (pS422), caracterizado porque se une específicamente al fragmento tau fosforilado de la SEQ ID Ns:9 y a la tau pS422, pero no se une a la tau ni al fragmento MCAK fosforilado de la SEQ ID Ns:17, es util para el tratamiento de una tauopatía.
ARP100102006A 2009-06-10 2010-06-08 Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales AR077016A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09007656 2009-06-10
EP09008487 2009-06-30

Publications (1)

Publication Number Publication Date
AR077016A1 true AR077016A1 (es) 2011-07-27

Family

ID=42753372

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102006A AR077016A1 (es) 2009-06-10 2010-06-08 Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales

Country Status (22)

Country Link
US (2) US8609097B2 (es)
EP (1) EP2440578B1 (es)
JP (2) JP2012529275A (es)
KR (1) KR101429367B1 (es)
CN (1) CN102459333B (es)
AR (1) AR077016A1 (es)
AU (1) AU2010257799B2 (es)
BR (1) BRPI1012993A2 (es)
CA (1) CA2762594C (es)
CL (1) CL2011003122A1 (es)
CO (1) CO6450613A2 (es)
CR (1) CR20110606A (es)
EC (1) ECSP11011514A (es)
IL (1) IL216509A0 (es)
MA (1) MA33339B1 (es)
MX (1) MX2011012837A (es)
NZ (1) NZ596187A (es)
PE (1) PE20120543A1 (es)
RU (1) RU2536247C2 (es)
SG (1) SG176754A1 (es)
TW (1) TW201103560A (es)
WO (1) WO2010142423A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10515A (es) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
RS58855B1 (sr) 2009-06-10 2019-07-31 Chugai Pharmaceutical Co Ltd Tetraciklična jedinjenja
JP4918630B1 (ja) 2010-08-20 2012-04-18 中外製薬株式会社 ４環性化合物を含む組成物
NZ609984A (en) 2010-10-11 2015-05-29 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
PL2758433T3 (pl) 2011-09-19 2018-06-29 Axon Neuroscience Se Oparta na białku terapia i diagnozowanie patologii zależnej od Tau w chorobie Alzheimera
JP6306513B2 (ja) * 2011-12-20 2018-04-04 ヤンセン バイオテツク，インコーポレーテツド 抗ＰＨＦ−ｔａｕ抗体及びその使用
HK1199891A1 (en) * 2011-12-21 2015-07-24 F. Hoffmann-La Roche Ag Rapid method for cloning and expression of cognate antibody variable region gene segments
ES2763361T3 (es) 2012-05-31 2020-05-28 Univ Osaka City Agente terapéutico o agente profiláctico para la demencia
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE FC RII SPECIFIC FC ANTIBODY
DK2889377T3 (da) 2012-08-24 2020-03-30 Chugai Pharmaceutical Co Ltd Fc?RIIb-Specifik Fc-regionsvariant
MX389105B (es) 2012-09-25 2025-03-20 Chugai Pharmaceutical Co Ltd Inhibidor de quinasas reordenadas durante la transfeccion (ret).
WO2014096321A1 (en) * 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
PE20161032A1 (es) * 2013-12-20 2016-10-19 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
KR20220042486A (ko) 2014-04-25 2022-04-05 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
EP3207057A2 (en) * 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anti-alpha-synuclein antibodies and methods of use
DK3221349T3 (da) * 2014-11-19 2021-01-04 Axon Neuroscience Se Humaniserede tau-antistoffer i Alzheimers sygdom
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
CA2973857C (en) 2015-01-16 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Combination drug
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
EP3283169A4 (en) 2015-04-16 2019-03-20 Alder Biopharmaceuticals, Inc. USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF FOR THE TREATMENT, PREVENTION OR INHIBITION OF PHOTOPHOBY
CA2986942C (en) 2015-06-05 2025-07-22 Ac Immune Sa Anti-tau antibodies and their methods of use
AR105089A1 (es) * 2015-06-24 2017-09-06 Hoffmann La Roche ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
KR102742965B1 (ko) * 2015-07-06 2024-12-13 유씨비 바이오파마 에스알엘 타우 결합 항체
MX2017015817A (es) * 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
FI3334761T3 (fi) * 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
TW201738272A (zh) 2016-04-15 2017-11-01 艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
HRP20210522T1 (hr) 2016-07-12 2021-05-14 H. Lundbeck A/S Antitijela specifična za hiperfosforilirani tau i načini njihove uporabe
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
AU2017373884B2 (en) 2016-12-07 2024-11-14 Ac Immune Sa Anti-tau antibodies and methods of their use
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
MX2019009817A (es) * 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
CA3077247A1 (en) 2017-10-16 2019-04-25 Eisai R & D Management Co., Ltd. Anti-tau antibodies and uses thereof
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
CA3089923A1 (en) 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
JP7362636B2 (ja) 2018-03-05 2023-10-17 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｐｈｆ－タウ抗体及びその使用
CR20210179A (es) 2018-07-03 2022-05-23 Hoffmann La Roche OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058)
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
IL281079B2 (en) 2018-09-04 2024-12-01 Chugai Pharmaceutical Co Ltd Method of producing a tetracyclic compound
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
IL299292A (en) 2020-06-25 2023-02-01 Merck Sharp & Dohme Llc High-affinity antibodies to tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU681071B2 (en) 1991-12-06 1997-08-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Tools for the diagnosis and treatment of alzheimer's disease
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides

Also Published As

Publication number Publication date
KR101429367B1 (ko) 2014-08-11
MA33339B1 (fr) 2012-06-01
ECSP11011514A (es) 2012-01-31
AU2010257799B2 (en) 2013-10-17
CA2762594A1 (en) 2010-12-16
JP6513617B2 (ja) 2019-05-15
CN102459333A (zh) 2012-05-16
SG176754A1 (en) 2012-01-30
KR20120024952A (ko) 2012-03-14
AU2010257799A1 (en) 2011-12-01
US20130310541A1 (en) 2013-11-21
US20110059093A1 (en) 2011-03-10
CR20110606A (es) 2012-01-12
US8609097B2 (en) 2013-12-17
HK1166331A1 (en) 2012-10-26
IL216509A0 (en) 2012-02-29
WO2010142423A2 (en) 2010-12-16
PE20120543A1 (es) 2012-05-23
MX2011012837A (es) 2011-12-16
CA2762594C (en) 2017-02-28
CN102459333B (zh) 2015-07-15
JP2017031176A (ja) 2017-02-09
US9290567B2 (en) 2016-03-22
CO6450613A2 (es) 2012-05-31
WO2010142423A3 (en) 2011-05-26
CL2011003122A1 (es) 2012-07-20
TW201103560A (en) 2011-02-01
RU2011152816A (ru) 2013-07-20
EP2440578B1 (en) 2017-03-08
NZ596187A (en) 2013-11-29
EP2440578A2 (en) 2012-04-18
RU2536247C2 (ru) 2014-12-20
BRPI1012993A2 (pt) 2018-01-16
JP2012529275A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
AR077016A1 (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
CL2017003288A1 (es) Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214)
GT200900167A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano.
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
NO20074238L (no) Fiksert dosering av HER-antistoffer
GT201200189A (es) Antagonistas de pcsk9
GEAP202114672A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
DK1937721T3 (da) Anti-IL-23 antistoffer
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201490677A1 (ru) Связывающие антиген cd27l белки
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
CY1116488T1 (el) Αντισωματα anti-προπερδινης
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
PE20091969A1 (es) ANTICUERPOS ANTI-PirB

Legal Events

Date Code Title Description
FA Abandonment or withdrawal